|1.||Rudel, Lawrence L: 8 articles (06/2012 - 08/2002)|
|2.||Chang, Ta-Yuan: 7 articles (07/2015 - 01/2002)|
|3.||Aragane, K: 6 articles (09/2001 - 01/2000)|
|4.||Kusunoki, J: 6 articles (09/2001 - 01/2000)|
|5.||Chang, Catherine C Y: 5 articles (07/2015 - 01/2002)|
|6.||Fujinami, K: 5 articles (09/2001 - 01/2000)|
|7.||Kojima, K: 5 articles (09/2001 - 01/2000)|
|8.||Sakashita, Naomi: 4 articles (10/2015 - 11/2003)|
|9.||Tomoda, Hiroshi: 4 articles (12/2011 - 09/2007)|
|10.||Miyazaki, Akira: 4 articles (03/2006 - 09/2003)|
09/01/2005 - "The use of inhibitors of enzyme acyl-CoA: cholesterol acyltransferase (ACAT) seems to be a novel potential approach for a therapeutic treatment of dyslipidaemias and atherosclerosis. "
07/01/2006 - "Intravascular ultrasound assessment of novel antiatherosclerotic therapies: rationale and design of the Acyl-CoA:Cholesterol Acyltransferase Intravascular Atherosclerosis Treatment Evaluation (ACTIVATE) Study."
01/01/2007 - "Statin therapy alone and in combination with an acyl-CoA:cholesterol O-acyltransferase inhibitor on experimental atherosclerosis."
03/01/2006 - "Human acyl-CoA:cholesterol acyltransferase (ACAT) and its potential as a target for pharmaceutical intervention against atherosclerosis."
05/01/2002 - "Inhibitors of acyl-CoA: cholesterol acyltransferase(ACAT) present another strategy in treating atherosclerosis through direct inhibition of ACAT in macrophages of the arterial wall. "
04/01/2008 - "To investigate the polymorphism of acyl-coenzyme A: cholesterol acyltransferase 1(ACAT1) gene and its relationship with endogenous hypertriglyceridemia (HTG) in Chinese population. "
04/01/2008 - "[Analysis of acyl-coenzyme A: cholesterol acyltransferase 1 polymorphism in patients with endogenous hypertriglyceridemia in Chinese population]."
02/01/2006 - "The CRF-induced hypertriglyceridemia, abnormal composition, and impaired clearance of triglyceride-rich lipoproteins and their remnants are primarily due to downregulation of lipoprotein lipase, hepatic lipase, and the very-low-density lipoprotein receptor, as well as, upregulation of hepatic acyl-CoA cholesterol acyltransferase (ACAT). "
11/01/2009 - "Hypertriglyceridemia, abnormal composition, and impaired clearance of triglyceride-rich lipoproteins and their remnants are mediated by down-regulation of lipoprotein lipase, hepatic lipase, very low-density lipoprotein (VLDL) receptor, and LDL receptor-related protein, relative reduction in ApoC-II/ApoC-III ratio, up-regulation of acyl-CoA cholesterol acyltransferase, and elevated plasma level of cholesterol ester-poor prebeta HDL. "
01/01/1997 - "Recent studies have shown that acyl-CoA:cholesterol acyltransferase (ACAT) plays an important role in the initiation of diabetes-associated hypercholesterolemia. "
01/01/1993 - "We have previously reported [J Lipid Res 1992; 33:1475-14841bd that the intestinal acyl-CoA:cholesterol acyltransferase (ACAT) plays a major role in the initiation of diabetes-associated hypercholesterolemia. "
05/01/1981 - "Hepatic acylcoenzyme A: cholesterol acyltransferase activity during diet-induced hypercholesterolemia in cynomolgus monkeys."
04/18/2008 - "Deletion of acyl-CoA:cholesterol O-acyltransferase 2 (ACAT2) in mice results in resistance to diet-induced hypercholesterolemia and protection against atherosclerosis. "
04/18/2008 - "Targeted deletion of acyl-CoA:cholesterol acyltransferase 2 (ACAT2) (A2), especially in the liver, protects hyperlipidemic mice from diet-induced hypercholesterolemia and atherosclerosis, whereas the deletion of ACAT1 (A1) is not as effective, suggesting ACAT2 may be the more appropriate target for treatment of atherosclerosis. "
05/01/2001 - "Postprandial hyperlipidemia in Zucker diabetic fatty fa/fa rats, an animal model of type II diabetes, and its amelioration by acyl-CoA:cholesterol acyltransferase inhibition."
02/23/2005 - "Acyl-CoA: cholesterol acyltransferase (ACAT), which plays a role in the absorption, storage, and production of cholesterol, has been explored as a potential target for pharmacological intervention of hyperlipidemia and atherosclerotic disease. "
05/01/1995 - "In the diabetic nontransgenic mice, enhanced intestinal acylCoA:cholesterol acyltransferase activity was demonstrated, a factor that may contribute to the development of diabetic hyperlipidemia. "
01/01/2000 - "Postprandial hyperlipidemia in streptozotocin-induced diabetic rats is due to abnormal increase in intestinal acyl coenzyme A:cholesterol acyltransferase activity."
01/01/1998 - "HL-004, N-(2,6-diisopropylphenyl) tetradecylthioacetamide, a novel acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor, was evaluated concerning the possible prevention of hyperlipidemia and atherosclerosis in 1% cholesterol-fed rabbits. "
|5.||Lecithin Acyltransferase Deficiency (Lecithin:Cholesterol Acyltransferase Deficiency)
09/01/2014 - "Lecitin cholesterol acyltransferase (LCAT) deficiency comprises a group of rare disorders related to HDL metabolism. "
11/01/2004 - "These abnormalities are, in part, due to acquired LCAT deficiency and upregulation of hepatic acyl-CoA:cholesterol acyltransferase (ACAT). "
12/01/1994 - "Familial plasma lecithine: cholesterol acyltransferase (LCAT) deficiency is a disease that is inherited as an autosomal recessing trait. "
01/01/1987 - "This finding confirms a deficiency of HDL lecithin:cholesterol acyltransferase activity (alpha-LCAT) in fish eye disease. "
01/01/1989 - "In the hypolipoproteinaemias, e.g., Tangier disease, generalised (alpha and beta) lecithin cholesterol acyltransferase (LCAT) deficiency, and alpha-LCAT deficiency (fish-eye disease), the absence or abnormality of HDL may impair clearance of endogenous and possibly exogenous stromal lipid. "
|2.||Lipase (Acid Lipase)
|3.||Lipoprotein Lipase (Diacylglycerol Lipase)
|4.||Acyl Coenzyme A (Acyl CoA)
|6.||LDL Receptors (LDL Receptor)
|7.||Phosphatidylcholine-Sterol O-Acyltransferase (Lecithin Cholesterol Acyltransferase)
|8.||Pre-beta High-Density Lipoproteins
|10.||LDL-Receptor Related Protein 1 (LDL-Receptor Related Protein)